
Leqembi: Pioneering Alzheimer’s Drug Faces Challenge in Europe
While the initial headlines might seem discouraging, there’s always more to the story. 🌟
While the initial headlines might seem discouraging, there’s always more to the story. 🌟
University of Oxford research revealed groundbreaking findings that could reshape dementia prevention. Ozempic (AKA Semaglutide/Wegovy), a type-2 diabetes and weight-loss drug, seems to significantly reduce the risk of dementia.
The newest Alzheimer’s drugs, Kisunla and Leqembi, are the first to actually slow down Alzheimer’s. How do they compare to each other?
VIDEO + ARTICLE: Kisunla (generic name: Donanemab) slowed cognitive and functional decline 35%. Once-monthly infusions reduced Alzheimer’s plaque 84%.
Three FDA-Approved drugs, terazosin, doxazosin, and alfuzosin, have a happy side effect; they boost energy production in brain cells. New studies suggest this slows or prevents Dementia with Lewy Bodies.
A drug for Alzheimer’s, called Leqembi, might soon be given less often. Right now, patients get it through a drip every two weeks. The idea is to change this to once a month.
The unanimous 11-0 FDA vote clears an exciting path for this new Alzheimer’s drug.
South Korea joined other countries in approving LEQEMBI® (generic lecanemab) for mild cognitive impairment, mild and early Alzheimer’s. Learn how Leqembi is treating Alzheimer’s around the world.
In a span of 40 years, why did average brain size increase and dementia rates drop? A new UC-Davis study explores environmental factors behind this silent revolution.
“People with dementia living in nursing homes and in the community were prescribed less and we did not detect negative health impacts for these groups.”
Got enough sunshine? Learn how sunshine seems to offer a bright, simple way to lower your risk of dementia.
Strength is not in our muscles. It is in our soul and spirit.
Lighting affects how people feel. The right light reduces agitation and improves mood in people with dementia.
SHORT-TERM MEMORY lapses are obvious signs of Alzheimer’s, but other tell-tale signals begin to show much earlier. Learn how to look for semantic impairments, such as simple questions about size.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
No spam, only news and updates.